PIK3CG and neoplasm: MYH9 overexpression can inhibit the PI3K/AKT signaling pathway, leading to increased p-PI3K and p-AKT levels, which in turn participate in tumor cell progression (Xiong et al., 2012; Xiong et al., 2021; Zhang et al., 2023).